TISSUE REGENIX GROUP PLC - ORD 0.1P
TISSUE REGENIX GROUP PLC - ORD 0.1P
Aktie · GB00B5SGVL29 (XLON)
Übersicht Finanzkennzahlen
0,32 GBP
0,63 % 0,002 GBP
Schlusskurs XLON 06.06.2025: 31,70 GBX
London (XLON) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 14:49

Aktuelle Kurse von TISSUE REGENIX GROUP PLC - ORD 0.1P

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XLON: London
London
TRX.L
GBX
06.06.2025 14:49
31,70 GBX
31,10 GBX
+1,93 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
0,00 % -0,94 % -3,94 % -23,06 % -44,39 % -53,72 % -14,32 %

Profil de l'entreprise pour TISSUE REGENIX GROUP PLC - ORD 0.1P Action

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.

Données de l'entreprise

Nom TISSUE REGENIX GROUP PLC - ORD 0.1P
Société Tissue Regenix Group plc
Site web https://www.tissueregenix.com
Marché d'origine XLON London
ISIN GB00B5SGVL29
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Mr. Daniel Ray Lee
Capitalisation boursière 26 Mio
Pays Royaume-Uni
Devise GBP
Employés 0,1 T
Adresse Unit 3, LS25 2GY Garforth
Date d'introduction en bourse 2006-12-21

Fractionnements d'actions

Date Fractionnement
28.04.2023 1:100
29.06.2010 1:5

Symboles boursiers

Nom Symbole
London TRX.L

Autres actions

Les investisseurs qui détiennent TISSUE REGENIX GROUP PLC - ORD 0.1P ont également les actions suivantes dans leur portefeuille :
ALM. BRAND A/S NAM. DK 10
ALM. BRAND A/S NAM. DK 10 Action
MORGAN STANLEY 25/36 FLR
MORGAN STANLEY 25/36 FLR Obligation
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025